Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

Latest News
August 16th 2025

Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML

August 11th 2025

Long-Term Follow-Up Affirms Ivosidenib's Sustained Benefit in IDH1-Mutated AML

July 31st 2025

Upfront HSCT More Cost-Effective for Patients With AML in Remission

July 30th 2025

Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL

July 14th 2025

Obe-Cel Is Effective Irrespective of Age in Relapsed/Refractory B-ALL

Video Interviews
View All
August 14th 2025

Considerations for Patient Monitoring Following CAR T and Bispecific Administration: Amir Fathi, MD

July 23rd 2025

Expertise Is Essential to Bispecific Access for Patients With Acute Leukemias: Amir Fathi, MD

July 20th 2025

Revumenib’s Safety Profile and Path to Formulary: Ivo Abraham, PhD, RN

July 1st 2025

Early SYRUS Data Highlight Safety, Efficacy of AZD0486 in Relapsed/Refractory B-Cell ALL: Ibrahim Aldoss, MD

June 29th 2025

Drivers of Cost Savings for Revumenib for Rare Acute Leukemias: Ivo Abraham, PhD, RN

June 28th 2025

SYRUS Study Explores AZD0486 Safety, Dosing in Relapsed/Refractory B-Cell ALL: Ibrahim Aldoss, MD

June 26th 2025

Revumenib for Rare Acute Leukemias Is Cost-Neutral for Health Plans: Ivo Abraham, PhD, RN

June 24th 2025

Beat AML Master Trial Finds Strong Response With Triplet Therapy: Ashley Yocum, PhD

July 13th 2024

W-T7 Shows Encouraging Response Rate, Manageable Safety in Relapsed/Refractory T-ALL/LBL

More News

Artwork of community health care with a giant stethoscope and medicine bag | Image credit: TarikVision - stock.adobe.com.
July 5th 2025

Academic-Community Partnerships Bringing Cancer Care to Patients

Laura Joszt, MA
Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.
Hands holding | Image credit: Africa Studio - stock.adobe.com
June 27th 2025

Understanding Patient and Caregiver Burdens in Acute Leukemia Treatment

Laura Joszt, MA
Caregivers and patients with acute leukemia face unique challenges, prioritizing treatment preferences that impact quality of life and emotional well-being.
Doctor speaking to a female patient with obesity | Image credit: Studio Romantic - stock.adobe.com
June 18th 2025

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

Laura Joszt, MA
High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.
Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
June 12th 2025

Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

Laura Joszt, MA
Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.
Gene sequencing | Image Credit: RFBSIP - stock.adobe.com
June 11th 2025

Quality Improvement Project Enhances AML Genomic Testing Efficiency

Laura Joszt, MA
A new genomic testing algorithm enhances turnaround times for acute myeloid leukemia diagnostics, improving treatment decisions and patient care quality.
Multiracial group of serious young adults sitting | Image credit: Drobot Dean
June 4th 2025

ALL Disparities, Treatment Gaps: AYA Patients Face Unique Challenges

Laura Joszt, MA
Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and unmet needs for effective third-line treatments, highlighting urgent care gaps.
Stephen Strickland, MD, MSCI | Image credit: SCRI
May 13th 2025

Durability, Reduced Toxicity of CAR NK Therapy in AML May Aid Curative Treatment

Stephen Strickland, MD, MSCI Interview by Mary Caffrey
Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor natural killer (CAR NK) cell therapy. Toxicity with this therapy is lower than seen in many conventional CAR T-cell therapies.
CAR NK cells | Image credit: MD Anderson
May 12th 2025

For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone

Stephen Strickland, MD, MSCI Interview by Mary Caffrey
First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
FDA approved. | Image Credit: Pawel - stock.adobe.com
January 23rd 2025

Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS

Rose McNulty
The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Elias Jabbour, MD | Image credit: MD Anderson
January 22nd 2025

MRD and Other Predictors From FELIX for Obe-Cel Success in R/R B-ALL

Mary Caffrey Elias J. Jabbour, MD
Studies presented at ASH 2024 added to the understanding of real-world treatment and outcomes for patients with pediatric AML. | Image credit: LASZLO - stock.adobe.com
January 7th 2025

Studies Examine Real-World Pediatric AML Treatment and Outcomes

Kimberly Rath, PharmD
Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients treated for pediatric acute myeloid leukemia (AML).
Jennifer Vaughn, MD, smiling during a zoom interview
December 26th 2024

The Balance of Managing Younger Patients With MPNs for Long-Term Treatment

Laura Joszt, MA
There are a number of considerations both in the short and long term to consider when making treatment decisions for younger patients with myeloproliferative neoplasms (MPNs).
Older patients with AML or MDS do not always receive the same care recommendations, a study found | image credit: Orawan - stock.adobe.com
December 19th 2024

Canadian Study Highlights Care Variability for Older Patients With MDS/AML

Kimberly Rath, PharmD
A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), emphasizing the need for evidence-based guidelines.
AML cells | Image Credit: © LASZLO - stock.adobe.com
December 17th 2024

Researchers Characterize Defining Feature of Pediatric AML Subtype

AJMC Contributor
Recently recognized by the World Health Organization, acute myeloid leukemia (AML) with t(7;12)(q36;p13) has previously been associated with MNX1 and ETV6 signaling, although MNX1::ETV6 fusion transcripts have only been confirmed in approximately half of cases.
Graphic with the words "The Top 5 ALL/AML Content in 2024" on a red background with health care icons along the top
December 16th 2024

Top 5 Most-Read ALL/AML Articles in 2024

Laura Joszt, MA
New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.
AML Acute Myeloid Leukemia | Image Credit: © momius-stock.adobe.com
December 7th 2024

Receiving ASCT After First CR May Improve Certain Outcomes in AML

AJMC Contributor
The meta-analysis found indications that autologous stem cell transplantation (ASCT) is associated with higher rates of disease-free survival and relapse-free survival, as well as lower rates of relapse compared with chemotherapy after patients achieved their first complete response (CR).
Nurse holding older woman's hands | Image credit: Cecilie Arcurs:peopleimages.com - stock.adobe.com
November 30th 2024

New CPX-351 Data Underscore Complexity of Treating AML in Older Patients 

Jared Kaltwasser
Phase 2 data show about half of patients with high-risk or secondary acute myeloid leukemia achieved a complete response or complete response with incomplete hematologic recovery after one or two cycles of induction therapy with CPX-351.
Doctor carrying documentation for patient care | image credit: Kanisorn - stock.adobe.com
November 29th 2024

Advent of Ponatinib for Ph+ ALL Expected to Influence New Guidelines

Kyle Munz
With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), updated guidelines could be on the horizon.
FDA Approval | image credit: gomixer - stock.adobe.com
November 26th 2024

FDA Approves Imatinib Oral Solution for Treatment of Various Cancers

Kyle Munz
The FDA approval marks the first oral solution indicated for patients with different forms of leukemia.
AML cells concept | image credit: sovova - stock.adobe.com
November 21st 2024

Study Reveals Leukemia Transplant Successes and Persistent Relapse Risks

Kimberly Rath, PharmD
Long-term survival rates for patients with leukemia after hematopoietic cell transplantation (HCT) are encouraging but personalized transplant strategies remain important to improve outcomes.
FDA approval stamp | Image Credit: Surendra - stock.adobe.com
Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Kristi Rosa
Revumenib has been approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older.
Genes - CrazyJuke - stock.adobe.com
November 15th 2024

NUP98 Rearrangements Linked to Poor Outcomes in AML

Kimberly Rath, PharmD
Findings of a recent study indicate that NUP98 rearrangements can significantly impact outcomes in patients with acute myeloid leukemia (AML).
FDA approval stamp | Image credit: BHM-stock.adobe.com
November 8th 2024

FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia

Laura Joszt, MA
The chimeric antigen receptor T-cell therapy obecabtagene autoleucel received approval to treat patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia.
Tacrolimus | Image Credit: © MQ-Illustrations - stock.adobe.com
November 7th 2024

Tacrolimus Linked to Lower Acute GVHD Risk

Kimberly Rath, PharmD
Posttransplantation treatment with either tacrolimus or cyclosporine A results in favorable outcomes, but tacrolimus may be better at preventing severe graft-versus-host disease (GVHD), according to new study findings.
New therapies for AML and other blood cancers may be informed by the overexpression of 3 proteins | image credit: jovannig - stock.adobe.com
November 2nd 2024

New Work Highlights Proteins as Potential Novel AML Therapeutic Targets

Gayle Turim Dickstein
Three proteins—THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel targets for future therapies.
AML | Image Credit: © Andrey - stock.adobe.com
October 30th 2024

After HMA Resistance in AML, a New Possible Therapy Option

Gayle Turim Dickstein
When resistance to or failure of hypomethylating agents (HMAs) occurs in acute myeloid leukemia (AML), depleting a ligase called TOPORS may help.
Blood smear AML | image credit: Chansom Pantip - stock.adobe.com
October 20th 2024

FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML

AJMC Contributor
The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Rash is a common side effect of an idarucibin and cytarabine induction intervention for AML | image credit: Kittiphan - stock.adobe.com
October 16th 2024

Researchers Identify Potential Predictors of Rash During AML Induction Therapy

AJMC Contributor
The study showed that having pre-existing leukopenia and more favorable performance status was associated with a higher risk of rash.
Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML | image credit: Matthieu - stock.adobe.com
October 16th 2024

Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML

Jared Kaltwasser
Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the fms-like tyrosine kinase 3 (FLT3) gene.
AML cells | image credit: TheWaterMeloonProjec - stock.adobe.com
October 3rd 2024

New Study Further Illuminates PARP1 Expression in ALL, AML, CML With BCR::ABL1 p190+

Kimberly Rath, PharmD
Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical parameters.
1234>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo